Message
Meta Text Info
Fetching Project...
Project Description
The R-Pharm Group of companies plans to build a pharmaceutical production plant. The project will be implemented in the new promising city of Alatau (Kazakhstan), the land plot for which has already been allocated in partnership with Khan-Tengri Biopharma, the press service of the Prime Minister of Kazakhstan reported. The hub, which, according to the government, will create several hundred jobs, and products with local status will be supplied not only to the domestic market, but also for export, is planned to be implemented within three years. The company has also committed to reducing the cost of medicines for consumers by about 20% every three years, offsetting this through exports. The launch of the plant will ensure the stability of prices for manufactured products. The joint venture will produce vital and strategic drugs for the country — this is a matter of national security.
Project Phase:
Initiation & Feasibility
Investment Value:
200 000 000 $
Location:
Value
Start Date:
11/1/2025
End Date:
11/1/2028
Involved Companies
Company:
░░░░░░░░░░░
Role:
░░░░░░░░░░░░░░░░░░░░░░░
Address:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
Phone:
░░░░░░░░░░░░░░░░░░░░░░░
Email:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
Website:
░░░░░░░░░░░░░░░░░░░░░░░░
Other links:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
Key Contacts
Name:
░░░░░░░░░░░░░░░░
Position:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
Phone:
Value
Email:
Value
Links:
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
Name:
Value
Position:
Value
Phone:
Value
Email:
Value
Links:
Value
Company:
Value
Role:
Value
Address:
Value
Phone:
Value
Email:
Value
Website:
Value
Other links:
Value
Key Contacts
Name:
Value
Position:
Value
Phone:
Value
Email:
Value
Links:
Value
Name:
Value
Position:
Value
Phone:
Value
Email:
Value
Links:
Value
Company:
VALUE
Role:
Value
Address:
Value
Phone:
Value
Email:
Value
Website:
Value
Other links:
Value
Key Contacts
Name:
Value
Position:
Value
Phone:
Value
Email:
Value
Links:
Value
Name:
Value
Position:
Value
Phone:
Value
Email:
Value
Links:
Value
Company:
VALUE
Role:
Value
Address:
Value
Phone:
Value
Email:
Value
Website:
Value
Other links:
Value
Key Contacts
Name:
Value
Position:
Value
Phone:
Value
Email:
Value
Links:
Value
Name:
Value
Position:
Value
Phone:
Value
Email:
Value
Links:
Value
Company:
VALUE
Role:
Value
Address:
Value
Phone:
Value
Email:
Value
Website:
Value
Other links:
Value
Key Contacts
Name:
Value
Position:
Value
Phone:
Value
Email:
Value
Links:
Value
Name:
Value
Position:
Value
Phone:
Value
Email:
Value
Links:
Value
Other important details
Khan-Tengri Biopharma was incorporated on March 6, 2025, just a few months before it appeared on the agenda of the Investment Headquarters. Officially, the company is building a full-cycle biopharmaceutical complex in the Alatau free Economic Zone, but there is no information about its production facilities and completed projects. The State Revenue Committee evaluates the tax risk as average. The company is headed by Askar Karimullin, who previously held senior positions at the Samruk-Kazyna Fund and BTA Bank. Until April 21, 2025, Karimullin was the sole founder, after which TengriX Ltd., which he also headed, joined the company as a co-founder. Co-owners of TengriX Ltd. These are Khan Tengri Capital, R-Pharm JSC and Sima Ltd.
The project involves the conclusion of an investment agreement with the Government of Kazakhstan and its implementation within three years. The products will be supplied not only to the domestic market of Kazakhstan, but also for export.
The company has committed to reducing the cost of medicines for consumers by about 20% every three years, offsetting this through exports.
The project is planned to be implemented in the new city of Alatau, the site for which has already been allocated. This was announced by Nikolay Zemskov, director of R-Pharma, on the sidelines of KGIR-2025, the government's press service reports.
"We have created a joint venture that is awaiting the conclusion of an investment agreement with the Government of the Republic of Kazakhstan. The project was approved by the investment headquarters. We were given a plot of land in the most promising city of the future, Alatau," Nikolai Zemskov said.
Publication/Revision Date:
11/3/2025